Appendix
1 bite per day (3) . Sexual transmission of Zika virus was included in the model for persons >15 years of age and in a monogamous context. The frequency of sexual encounters for partnered persons was sampled from age-dependent distributions (Appendix Tables 2 and 3 ). For an individual in the age group , the partner was selected from the age group ± 5 years of age.
Upon successful Zika virus transmission, susceptible persons entered an intrinsic incubation period (IIP), sampled for each person from the associated distribution (6, 7) . After the IIP elapsed, a fraction (sampled between 40% to 80%) of infected persons entered asymptomatic infection without developing clinical symptoms (8, 9) . In our previous studies (3, 10) , Zika virus transmission from asymptomatic infection was modeled by a relative transmissibility factor compared with symptomatic infection, which ranged from 0.1 to 0.9. Here we assumed the same transmissibility for both asymptomatic and symptomatic infection, with any transmission reduction in asymptomatic infection accounted for in the calibration process.
Persons who recovered from either asymptomatic or symptomatic infection were assumed to be immune to reinfection for the remainder of the simulation time. A schematic diagram of the model for transmission dynamics, natural history of Zika virus infection, and disease outcomes are provided in Appendix Figure 2 . All parameters pertaining to infection dynamics are summarized in Appendix Table 5 . Incidence and attack rates for different countries in the absence of vaccination are illustrated in Appendix Figures 3 and 4. The total number of pregnant women was calculated based on the country-specific fertility rate of population in each simulation (Appendix Table 4 ). Ignoring fatal complications, the number of pregnant women at any point in time for each simulation was calculated by the following (14):
where nWRA is the number of women of reproductive age, with an abortion rate of 12%. Initial vaccine coverage of women of reproductive age was 60% (at the start of simulations). Initially and during the epidemic simulations, vaccination coverage of pregnant women was set to 80%.
Zika virus-infected persons with symptoms were assumed to incur short-and long-term direct medical costs related to hospitalization, treatment, and long-term sequelae. Costs for different categories are summarized in Appendix 
Additional Scenarios
Future Zika virus outbreaks may occur with different attack rates from those estimated for the 2015-2017 outbreaks. Therefore, we conducted cost-effectiveness analysis for 2 additional scenarios. In the first scenario, we calibrated the model to an increase of 4% in the estimated attack rate for each country. In the second scenario, the model was calibrated to a 4% decrease in the estimated attack rates, with a lower bound of 1%, for each country. The levels of preexisting herd immunity at the onset of simulations remained the same as those in the Table in the main article.
In the scenario with increased attack rates, the results show that the vaccine is very costeffective (using per-capita GDP as the threshold) for a VCPI up to $20 in Nicaragua and up to $50 in French Guiana (Appendix Figure 6 ). The upper VCPI for other countries ranged between these values. Similarly, using 3 times the per capita GDP as the threshold, the vaccine is still cost-effective for a VCPI up to $26 in Nicaragua and up to $98 in French Guiana (Appendix Figure 6 ). In the scenario with decreased attack rates, the vaccine is (very) cost-effective for a VCPI up to ($4) $9 in Mexico and up to ($41) $84 in French Guiana (Appendix Figure 7) , with other countries having an upper VCPI value in this range. Summaries of the cost-effectiveness analysis for both scenarios of higher and lower attack rates are provided in Appendix Tables 9   and 10 .
We also calculated the percentage reduction of microcephaly during pregnancy for both scenarios of increased and decreased attack rates. We found that the median percentage reduction in both scenarios was >75% in all countries (Appendix Figure 8 ). Appendix Table 3 . Age-dependent probability matrix of sexual encounters for females (5) .
Age groups
Weekly frequency of sexual encounters for females 0 
